-transparent.png){kind=logo}
Debrisoquine hydroxylation in a Polish population. 1995
P K Kunicki, and
D Sitkiewicz, and
A Pawlik, and
V Bielicka-Sulzyc, and
E Borowiecka, and
B Gawrońska-Szklarz, and
R Sterna, and
H Matsumoto, and
M Radziwoń-Zaleska
Department of Clinical Biochemistry, National Institute of Cardiology, Warszawa, Poland.
The genetic polymorphism of drug oxidation mediated by cytochrome P450IID6 (CYP2D6) was determined in 154 Polish volunteers using debrisoquine as the test substance. The results showed a bimodal distribution of the debrisoquine metabolic ratio (MR). Nine persons (5.8%) with MR > 12.6 were classified as poor metabolisers (gene frequency 0.242), which is in substantial agreement with the data reported for other Caucasian populations.
Related Publications
P K Kunicki, and
D Sitkiewicz, and
A Pawlik, and
V Bielicka-Sulzyc, and
E Borowiecka, and
B Gawrońska-Szklarz, and
R Sterna, and
H Matsumoto, and
M Radziwoń-Zaleska
November 1991,
Pharmacogenetics,
P K Kunicki, and
D Sitkiewicz, and
A Pawlik, and
V Bielicka-Sulzyc, and
E Borowiecka, and
B Gawrońska-Szklarz, and
R Sterna, and
H Matsumoto, and
M Radziwoń-Zaleska
September 1990,
Zhongguo yao li xue bao = Acta pharmacologica Sinica,
P K Kunicki, and
D Sitkiewicz, and
A Pawlik, and
V Bielicka-Sulzyc, and
E Borowiecka, and
B Gawrońska-Szklarz, and
R Sterna, and
H Matsumoto, and
M Radziwoń-Zaleska
November 1980,
Xenobiotica; the fate of foreign compounds in biological systems,
P K Kunicki, and
D Sitkiewicz, and
A Pawlik, and
V Bielicka-Sulzyc, and
E Borowiecka, and
B Gawrońska-Szklarz, and
R Sterna, and
H Matsumoto, and
M Radziwoń-Zaleska
November 1980,
Xenobiotica; the fate of foreign compounds in biological systems,
P K Kunicki, and
D Sitkiewicz, and
A Pawlik, and
V Bielicka-Sulzyc, and
E Borowiecka, and
B Gawrońska-Szklarz, and
R Sterna, and
H Matsumoto, and
M Radziwoń-Zaleska
October 1987,
Lancet (London, England),
P K Kunicki, and
D Sitkiewicz, and
A Pawlik, and
V Bielicka-Sulzyc, and
E Borowiecka, and
B Gawrońska-Szklarz, and
R Sterna, and
H Matsumoto, and
M Radziwoń-Zaleska
October 1996,
Pharmacogenetics,
P K Kunicki, and
D Sitkiewicz, and
A Pawlik, and
V Bielicka-Sulzyc, and
E Borowiecka, and
B Gawrońska-Szklarz, and
R Sterna, and
H Matsumoto, and
M Radziwoń-Zaleska
October 1977,
Lancet (London, England),
P K Kunicki, and
D Sitkiewicz, and
A Pawlik, and
V Bielicka-Sulzyc, and
E Borowiecka, and
B Gawrońska-Szklarz, and
R Sterna, and
H Matsumoto, and
M Radziwoń-Zaleska
August 1992,
Acta neurologica Scandinavica,
P K Kunicki, and
D Sitkiewicz, and
A Pawlik, and
V Bielicka-Sulzyc, and
E Borowiecka, and
B Gawrońska-Szklarz, and
R Sterna, and
H Matsumoto, and
M Radziwoń-Zaleska
January 1997,
European journal of clinical pharmacology,
P K Kunicki, and
D Sitkiewicz, and
A Pawlik, and
V Bielicka-Sulzyc, and
E Borowiecka, and
B Gawrońska-Szklarz, and
R Sterna, and
H Matsumoto, and
M Radziwoń-Zaleska
December 1990,
Lancet (London, England),
